Vosevi & Mavyret: The Impact of New Options for DAA-Experienced Patients With HCV

Updated
Latest ClinicalThought commentaries from Clinical Care Options (CCO).

Over at Clinical Care Options, using an easy to follow patient case scenario experts discuss treatment options with newly approved drugs: Mavyret (glecaprevir/pibrentasvir) GLE/PIB and Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) SOF/VEL/VOX.

11/16/2017

The Impact of New Options for DAA-Experienced Patients With HCV

Jordan J. Feld MD, MPH - 11/16/2017

With the approvals of SOF/VEL/VOX and GLE/PIB, what is the new management approach for DAA-experienced patients with HCV infection?

In this viral hepatitis case series, we highlight common patient case scenarios and the critical decision making that informs selection of optimal patient management strategies. This commentary features a woman with cirrhosis who is seeking retreatment after failure of first-line direct-acting antiviral (DAA) therapy. The impact of the recent approvals of sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX) and glecaprevir (GLE)/pibrentasvir (PIB) on treatment for this class of patient is discussed.

Case Details
A 59-year-old white woman with compensated cirrhosis (elastography 24 kPa) and genotype 1a HCV infection was previously treated with SOF/ledipasvir (LDV) for 12 weeks, but she experienced a relapse at posttreatment Week 6. She reports strict adherence to her previous regimen and is seeking advice on retreatment options.
Continue reading @ CCO

11/15/2017
How Recent Drug Approvals Have Affected First-line HCV Treatment
Nancy Reau MD, FAASLD, AGAF - 11/15/2017
What parameters now qualify a patient infected with HCV for shortened first-line therapy?

In this viral hepatitis case series, we highlight common patient case scenarios and the critical decision making that informs selection of optimal patient management strategies. This commentary features a treatment-naive, noncirrhotic patient who is infected with HCV and ready to begin therapy. The candidacy of this patient for 8-week vs 12-week therapy is discussed, with a focus on the latest treatment options and guidelines.

Case Details
A 56-year-old white man newly diagnosed with genotype 1a HCV infection presents for initiation of treatment. His baseline HCV RNA is 8,500,000 IU/mL and he has F2 fibrosis. He expresses a desire to take as short a course of HCV treatment as possible.
Continue reading @ CCO

*Free registration is required